openPR Logo
Press release

Olaparib Bevacizumab by Astrazeneca expected to drive market size of Metastatic Colorectal Cancer

03-11-2024 05:59 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Olaparib Bevacizumab by Astrazeneca expected to drive market

[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on Olaparib Bevacizumab (Astrazeneca) providing insights into the drug market landscape and market forecast of Olaparib Bevacizumab upto 2032. The report, titled "Olaparib ± bevacizumab Market Size, Forecast, and Emerging Insight - 2032" is now available for review and analysis.
Are you interested in finding out the projected market size of Olaparib Bevacizumab in 2032? Olaparib Bevacizumab Market Forecast
https://www.delveinsight.com/report-store/olaparib-bevacizumab-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
The Olaparib Bevacizumab Market Report offers projected sales forecasts for Olaparib Bevacizumab for indications until 2032, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of competitors and marketed products indication. It also covers analyst views along with market drivers and barriers.
Astrazeneca Olaparib Bevacizumab is serving as a beacon of hope for the patients suffering from Metastatic Colorectal Cancer.
What is an Olaparib Bevacizumab Prescribed for?
The Food and Drug Administration has broadened the approval of olaparib (LYNPARZA, AstraZeneca Pharmaceuticals, LP) to encompass its use in combination with bevacizumab for the initial maintenance therapy of adult individuals with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. This applies to patients who have achieved complete or partial response following initial platinum-based chemotherapy and whose cancer is linked to homologous recombination deficiency positive status, characterized by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.

The report extensively covers the details and developments related to Olaparib Bevacizumab, capturing important highlights on developmental pipeline, regulatory status and special designations of Olaparib Bevacizumab, route of administration, safety and efficacy details.

Olaparib Bevacizumab Market Assessment
This report provides a detailed market assessment of Olaparib Bevacizumab for Metastatic Colorectal Cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2032.

Olaparib Bevacizumab Clinical Assessment
The report provides the clinical trials information of Olaparib Bevacizumab for Metastatic Colorectal Cancer covering trial interventions, trial conditions, trial status, start and completion dates. Report also includes important insights on regulatory milestones and other developmental activities related.
Do you know your drug's competitive positioning against Olaparib Bevacizumab? Olaparib Bevacizumab Drugs Insights
https://www.delveinsight.com/report-store/olaparib-bevacizumab-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Olaparib Bevacizumab Competitive Landscape
The report offers insights into the key players and companies actively engaged in the development of the specified indication. It provides valuable information regarding the competitive positioning of the Olaparib Bevacizumab.

Olaparib Bevacizumab Market Size in the US
A dedicated section of the report focuses on the expected market size of Olaparib Bevacizumab for the United States. DelveInsight's analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders.

Key Highlights of Olaparib Bevacizumab:

• The report contains forecasted sales of Olaparib Bevacizumab for indication till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Metastatic Colorectal Cancer.
• The report also features the qualitative and quantitative analysis with analysts as well as KOL views for Olaparib Bevacizumab in Metastatic Colorectal Cancer.
Stay ahead in competition by leveraging insights on Olaparib Bevacizumab market Report: Download Olaparib Bevacizumab Market Report
https://www.delveinsight.com/sample-request/olaparib-bevacizumab-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Why you should buy Olaparib Bevacizumab Market Report:
• The report provides future market assessments for Olaparib Bevacizumab for Metastatic Colorectal Cancer in the 7 Major Markets, Advance qualitative analysis like SWOT, expert analysts' views, detailed overview of market competitors, and short analysis of other emerging therapies in Ulcerative Colitis.
• Leading Olaparib Bevacizumab for Metastatic Colorectal Cancer forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Olaparib Bevacizumab
• Discover the competitive landscape of Olaparib Bevacizumab through 7MM
• Get a Thorough Analysis of the Olaparib Bevacizumab Development pipeline, Safety & Efficacy of the Olaparib Bevacizumab, and ROA
• Thorough Olaparib Bevacizumab market forecast will help understand how drug is competing with other emerging Olaparib Bevacizumab
• Get analysis of the Olaparib Bevacizumab clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
• Drug Market forecasts are calculated after taking into consideration KOL viewpoints

Related Reports By DelveInsight:

Metastatic Colorectal Cancer Pipeline https://www.delveinsight.com/report-store/metastatic-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's, "Metastatic Colorectal Cancer Pipeline Insight, 2024" report provides comprehensive insights about 130+ companies and 140+ pipeline drugs in the Metastatic Colorectal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. The key companies developing therapies include - SFJ Pharmaceuticals, Merck Serono, Sumitomo PharmaCo.,Ltd., Immunovative Therapies,Ltd., Cardiff Oncology, Symphogen A/S, Genentech, Qilu Pharmaceutical Co.,Ltd., Henlix Biotech, Scandion OncologyA/S, Aadi Bioscience,Inc., Novartis, Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co.,Ltd., Menarini Group, ChiaTai Tianqing Pharmaceutical Group Co.,Ltd., Arcus Biosciences,Inc., Roche, Boehringer Ingelheim, Isofol Medical, Treos Bio, Suzhou Suncadia Biopharmaceuticals Co.,Ltd., Elevar Therapeutics, Shanghai HenliusBiotech, and others.
It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Top Services Offered By DelveInsight:

Explore success with our case study on R&D, Manufacturing & Commercial Capabilities. Uncover insights for strategic growth in the industry. https://www.delveinsight.com/case-study/r-and-d-landscape-assessment

Latest Reports Offered By DelveInsight:

Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products.

Symptomatic Partial-thickness Rotator Cuff Tears Market
https://www.delveinsight.com/report-store/symptomatic-partial-thickness-rotator-cuff-tears-market
DelveInsight's "Symptomatic Partial-thickness Rotator Cuff Tears Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Symptomatic Partial-thickness Rotator Cuff Tears, historical and forecasted epidemiology as well as the Symptomatic Partial-thickness Rotator Cuff Tears market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market
https://www.delveinsight.com/report-store/zika-virus-market
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Olaparib Bevacizumab by Astrazeneca expected to drive market size of Metastatic Colorectal Cancer here

News-ID: 3423373 • Views:

More Releases from DelveInsight Business Research

Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibrillation Space by DelveInsight
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals. Objective of the Case Study The
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestones, Therapies in Development, Mechanisms of Action, and Routes of Administration - By DelveInsight
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics. According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Rising Cancer Burden and Technological Advancements, states DelveInsight
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies. Biopsy devices play a crucial role in disease diagnosis by
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven by Rising Surgical Procedures, Technological Advancements, and Growing Adoption of Minimally Invasive Techniques, States DelveInsight
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide. DelveInsight's General Surgery Devices Market Report 2032 provides

All 5 Releases


More Releases for Olaparib

ER+/HER2 Breast Cancer Market: Epidemiology, Pipeline Products, Companies Workin …
DelveInsight's "ER+/HER2 Breast Cancer - Market Insights, Epidemiology and Market Forecast- 2034" report delivers an in-depth understanding of the ER+/HER2 Breast Cancer, historical and forecasted epidemiology as well as the ER+/HER2 Breast Cancer market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. Emerging therapies for ER+/HER2 breast cancer-such as KISQALI (ribociclib), IBRANCE (palbociclib), AFINITOR (everolimus), LYNPARZA (olaparib), Elacestrant, Giredestrant (RG6171/GDC-9545), Camizestrant (AZD9833), LY3484356
03-24-2025 | Health & Medicine
FactMR
Olaparib API Market Projected to Grow at 15.3% CAGR to US$ 4.41 Billion by 2034
The global olaparib active pharmaceutical ingredient (API) market is poised for significant growth over the next decade, driven by the expanding application of olaparib in oncology treatments and the increasing prevalence of various cancers worldwide. According to a new industry report released by Fact.MR, revenue from the global olaparib API market is estimated at US$ 1.07 billion in 2024 and has been evaluated to increase at an excellent CAGR of
ER+/HER2- Breast Cancer Market: Analysis of Epidemiology, Pipeline Products, and …
ER+/HER2- Breast Cancer emerging therapies such as KISQALI (ribociclib), IBRANCE (palbociclib), AFINITOR (everolimus), LYNPARZA (olaparib), Elacestrant, Giredestrant (RG6171, GDC-9545), Camizestrant (AZD9833), LY3484356 (imlunestrant), Lerociclib (EQ132), and others are expected to boost the ER+/HER2- Breast Cancer Market in the upcoming years. DelveInsight has launched a new report on "ER+/HER2- Breast Cancer - Market Insights, Epidemiology, and Market Forecast-2032" that delivers an in-depth understanding of the ER+/HER2- Breast Cancer, historical and forecasted epidemiology
Olaparib Market Size and Forecast
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Olaparib Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion. Olaparib Market Size And Scope The Olaparib market is experiencing significant growth, driven by its effectiveness as a PARP inhibitor in treating various cancers, including ovarian, breast,
Global and United States Olaparib Drugs Market Report & Forecast 2022-2028
This report focuses on global and United States Olaparib Drugs market, also covers the segmentation data of other regions in regional level and county level. Global Olaparib Drugs Scope and Market Size Olaparib Drugs market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Olaparib Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental
Olaparib Market Research and Development with Growth Analysis from 2021 to 2027
Latest released, the research study on Global Olaparib Market Research Report 2021, report comprises growth rate, size, analysis by type, market segment by Application, market competition by manufacturers, share by region, manufacturing cost analysis, Also, the Olaparib Market offers market breakdown, competitive situation and trends, key raw materials analysis, dynamics, forecast by type, by application and revenue estimates with covid-19 impact till 2027. Get Free sample copy of the report Here: https://www.marketintelligencedata.com/reports/562779/global-olaparib-sales-market-report-2021/inquiry?Mode=kalyani The